Dr Graeme Alexander
Dr Alexander worked as a research fellow in the Liver Unit at King's College Hospital with Professors Roger Williams and Adrian Eddleston, progressing to Senior Lecturer. He was appointed University Lecturer in Hepatology and Medicine at Cambridge University in 1991, a joint appointment as Consultant Hepatologist with Addenbrooke's Hospital to establish the hepatology service and provide support for the surgical liver transplant team led by Professor Sir Roy Calne.
He was director of Liver services between 1991 and 2007 and director of specialist gastroenterology training between 2000 & 2005. He was a founding member of HCV Research UK, UK-PBC, PSC-UK, as well as the nascent groups AIH-UK & HCC-UK and remains active in each of these.
Professor Robert Goldin
Professor Goldin is Professor of Liver and Gastro-intestinal Pathology at Imperial College and Head of Gastro-intestinal Pathology at Imperial College NHS Trust. He also works at the Ludwig Institute for Cancer Research in Oxford.
He is the lead histopathologist for upper GI cancer for the West London Cancer Network and frequently receive cases for a second opinion. As the histopathologist for the endoscopic mucosal resection group at Imperial, he is part of a pan-European network developing new approaches for the diagnosis and treatment of pre-invasive and early oesophageal and gastric cancer. His current research in GI cancer includes the application of metabonomics to the diagnosis of upper and lower GI tract malignancy, the development of techniques for the assessment of GI cancers to neoadjuvant therapy and studies of lymphangiogenesis and angiogenesis in predicting this response.
Dr Andrew Wotherspoon
Dr Wotherspoon trained at University College London and in 1996 he joined the Royal Marsden Hospital as a consultant histopathologist. For the last 16 years he has been the lead Haematopathologist and Gastrointestinal pathologist. During that time he has developed an interest in all aspects of the diagnosis and management of gastrointestinal cancer.
Dr Wotherspoon has co-authored over 200 papers in peer-reviewed journals, 23 book chapters and 3 books. He is a member of numerous learned societies and is involved the running of several national and international clinical trials.
Professor Derek Manas
Professor Manas is Professor of Transplantation at Newcastle University in 2007 and has been instrumental in successfully developing three super-regionally funded transplant programmes in the North East of England - namely: Liver, Pancreas and Islet transplantation. Professor Manas is also a member of a number of national committees including NICE, Liver and Pancreas Advisory Groups, British Transplant Society and ELTA. He is also Chair of the Transplant Surgeons Forum.
Professor Manas has been developing the UK's very first Institute for Transplantation on the Freeman Hospital site - a fully integrated facility dedicated to all aspects of transplantation - as well as fostering research and development all under one roof.
Daniel McGowan is currently a National Institute of Healthcare Research Healthcare Scientist Research Fellow based at the Department of Oncology, Oxford University. Previously, he was Deputy Head of Nuclear Medicine Physics at Oxford University Hospitals NHS Trust. He is one of the founding members of the Internal Dosimetry Users Group and served as Vice-Chair 2011-2013.
Dr Jill Tipping
Dr Tipping has been a practising Medical Physicist in the Department of Nuclear Medicine at the Christie NHS Foundation Trust since 2001, following previous careers in university research and the nuclear industry. She works on many forms of Radionuclide therapies with a special interest in dosimetry. Therapies covered include Thyroid ablation, mIBG, PRRT, and Radioimmunotherapy. She has been involved in the development of the SIRT service at Christie since the first patients in 2005.
The Christie is now one of the designated SIRT centres for the North West. During SIRT service at the Christie, Dr Tipping has compared Lung shunt measurements made from planar and SPECT measurements to help develop UK Guidelines. Her research interests include improving quantification in SPECT imaging through Monte Carlo Modelling.
Dr Nicola Mulholland
Dr Mulholland trained in medicine at Cambridge University and London Hospital Medical College, gaining a distinction in the final MBBS examination. She is dually accredited in radiology and nuclear medicine and was appointed at King's College Hospital NHS Foundation Trust, London, in 2007 as a Consultant Radiologist and Nuclear Medicine Physician.
In molecular medicine, Dr Mulholland has implemented the PET/CT and SPECT/CT services at King's College Hospital and specialises in hybrid functional imaging and radionuclide therapies, including SIRT. She is the Royal College of Physicians Nuclear Medicine representative for South Thames and sits on the Professional Standards Committee of the British Nuclear Medicine Society. Dr Mulholland is honorary senior lecturer at King's College London and teaches on MSc course in nuclear medicine.
Professor Ricky Sharma, Clinical Oncology
Ricky Sharma is Professor and Chair of Radiation Oncology at University College London and a Scientific Group Leader at the UCL Cancer Institute. He is also an Honorary Consultant in Clinical Oncology at University College London Hospitals and the Royal Free Hospital, where he has a clinical practice in radiotherapy and chemotherapy. Ricky Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic and on the multi-modality treatment of cancer with precision radiotherapy.
At a national level, Professor Sharma Co-Chairs the Early Phase Trials Workstream of the United Kingdom NCRI Clinical and Translational Radiotherapy (CTRad) Group and he leads an international collaboration between academia and pharmaceutical companies to develop new drug-radiotherapy combinations. Professor Sharma also leads randomised phase III clinical trials, including FOXFIRE which has recruited 364 patients with metastatic colorectal cancer across the UK. FOXFIRE is an example of what can be achieved through partnership between an academic institution (as sponsor), the NHS, the National Cancer Research Institute, Cancer Research UK and Sirtex Medical Ltd. Overall survival results from over 1000 patients in this research collaboration across several continents will be reported by Professor Sharma and colleagues from 2017 onwards.
Professor Daniel Palmer, Medical Oncology
Professor Palmer is North West Cancer Research Fund Professor and Honorary Consultant in Medical Oncology, University of Liverpool. His research interests relate to HPB cancers (liver, pancreas and biliary tract). He is a member of the NCRN Upper GI cancers clinical studies group, and the hepatobiliary and pancreatic sub-groups.
He has established a portfolio of early phase clinical trials and translational studies in this field as well as making significant contributions to multi-centre phase III trials and is Chief Investigator of NCRN102, a randomized study of BIBF1120 for patients with advanced hepatocellular carcinoma (HCC). He is UK chief investigator for the US CALGB80802 trial of doxorubicin with sorafenib for advanced HCC and for SORAMIC, a multinational study of the addition of SIRT to sorafenib in patients with liver predominant advanced HCC.
Dr Harpreet Wasan, Medical Oncology
Dr Wasan leads the gastrointestinal oncology clinical research programme at Hammersmith Hospital, Imperial College London, which is a dedicated oncology referral centre for complex colorectal cancer and liver metastases. He is on the UK National Cancer Research Institute (NCRI/NIHR) sub-committees of both the advanced colorectal cancer and the Hepato-biliary gastrointestinal groups.
Dr Wasan is Co-Chief Investigator for the FOXFIRE trial (phase III randomised CRC liver-metastases y90-radioembolisation) and has treated over 200 patients with this technology. He is also Chief Investigator for CUP-ONE, a global clinico-translational study of metastatic 'Cancer of unknown primary' looking at novel forms of rapid molecular diagnostic and treatment algorithms. He was also co-chief investigator of the advanced Biliary cancer Phase III trial (ABC02), which set the global standard of care. He has other UK national cancer consultative roles, journal involvement and is an invited faculty member of many international GI cancer conferences.
Clive Stone had a nephrectomy in 2007 following a diagnosis of kidney cancer. When he was diagnosed cancer patients had little in the way of treatment options, so he led over a hundred fellow kidney cancer patients and families to NICE HQ in London to protest. Over 34,000 cancer patients now receive drugs to give them extra time with their loved ones. He himself has subsequently had treatment with Sutent and repeated doses of radiotherapy to metastases.
Clive supports cancer patients as an Advocate and campaigns for more effective treatments. He also writes for the Oxford Mail to raise awareness of cancer and the value of radiotherapy. As a lay member, he is proud to be part of this excellent team with its innovative new radiotherapy option for patients.
Clint Waight, Lead Pharmacist for Radiopharmacy
Clint is the Lead Pharmacist for Radiopharmacy at the Royal Infirmary of Edinburgh, and is a member of the UK Radiopharmacy Group Strategic Committee. He qualified as a pharmacist in 1999 in Melbourne, Australia before coming to the UK in 2001. He worked as a senior clinical pharmacist in haematology and oncology at the Edinburgh Cancer Centre and the Victoria Hospital Kirkcaldy, before specializing in Radiopharmacy in 2013.
Clint and his team in Edinburgh have gained their experience with SIRT from participation in the FOXFIRE, SORAMIC and EPOCH trials, as well as continuing to provide SIRT to NHS patients referred from across Scotland.
Dr Jon Bell, Interventional Radiology
Dr Bell completed sub-specialty training in Interventional Radiology in Manchester and was appointed as a Consultant Radiologist at The Christie in 2013. In 2015, he completed the European Board of Interventional Radiology. He is a member of the Faculty Board of Clinical Radiology at the Royal College of Radiologists and the Safety and Quality Committee of the British Society of Interventional Radiology.
Dr Bell works at a high volume SIRT centre and he has used this experience to produce accredited online learning material for the SIRT User Network. He has a strong interest in medical education and is an Associate Training Programme Director for Radiology at Health Education North West.
Dr Phil Boardman, Interventional Radiology
Dr Boardman trained in radiology with particular emphasis on Interventional Radiology in Oxford, London and Hull before taking up a consultant appointment in 1997. He is currently a Consultant Interventional Radiologist at the Oxford University Hospital NHS Trust, working at the Churchill Hospital. Over the past 10 years Dr Boardman has developed an increasing interest in the use of Interventional Radiology in cancer patients and this Interventional Oncology workload now forms the majority of his practice.
Dr Boardman is interested in locoregional treatment of hepatic malignancy using ablative and catheter-directed therapies. He was involved in the initial implementation of the SIRT programme in Oxford and continues to lead the radiological aspects of the programme.
Dr James Franklin, Diagnostic Radiology
Dr Franklin studied Clinical Medicine at the University of Cambridge and Imperial College, London. He completed Foundation Training at Brighton and Sussex University Hospitals and was awarded MRCP in 2009. He was appointed as a Specialist Trainee in Radiology in 2009, attained the FRCR in 2012 and has developed subspecialty interests in Gastrointestinal and Oncological Imaging.
Dr Franklin is currently a Clinical Research Fellow in the Oncology Department of the University of Oxford and the Radiology Department of the Oxford University Hospitals NHS Trust.
Dr Nicholas Paul Tait, Interventional Radiology
Dr Tait trained in radiology at University of Newcastle Hospitals and was appointed in March 2000 to the position of Consultant in Interventional Radiology at the Hammersmith Hospital, now part of Imperial College Healthcare NHS Trust.
Dr Tait's research interests include Gastrointestinal Imaging, Interventional and vascular radiology with specific reference to the liver and biliary tree, and oncological management. He is a member of the team that introduced radioembolisation management of live tumours (SIRT) into regular practice in the UK and has been instrumental in the training of other UK radiologists in this procedure.
Dr Graeme Weir, Interventional Radiology
Dr Weir completed a fellowship in interventional radiology at the University of British Columbia / Vancouver General Hospital, gaining experience in SIRT. Dr Weir has since been working at the Royal Infirmary of Edinburgh, as a Consultant Radiologist, specialising in Interventional Radiology and has been involved in the development of the radioembolisation programme along with radiology, oncology, nuclear medicine and radiopharmacy colleagues.
NHS Lothian have recruited several Scottish patients into the FOXFIRE trial and are also involved in the QUEST and PERFORM trials and have recently been commissioned to deliver SIRT to all eligible Scottish patients with metastatic colorectal and cholangiocarcinoma through the Commissioning through Evaluation process.
There is a restricted access forum for all clinicians involved in the SIRT procedure to help share best practice and experiences. If you have or you would like to share your experiences or you want to find out more about the procedure and the latest clinical developments, please join our community.
Click here to join or sign-in
There is a designated site for SIRT patients, their families and carers called My SIRT Story.
Click here to find out more